Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness. (September 2015)

• Record Type: Journal Article
• Authors: Poolman, Jan T; Richmond, Peter
• Is Part Of: Expert review of vaccines. Volume 14:Number 9(2015)
• Page Start: 1277
• Page End: 1287
• Publication Date: 2015-09
• Subjects: Vaccines -- Periodicals; Vaccination -- Periodicals; 615.37205
• Languages: English
• ISSNs: 1476-0584

Abstract

<abstract> <title> <x xml:space="preserve">Abstract</x> </title> <p>Vaccines targeting <italic>Neisseria meningitidis</italic> serogroup B (MenB) have been attempted for 40 years. Monovalent outer membrane vesicle vaccines targeted at epidemic outbreaks have been successfully developed. Newer vaccines aim to induce antibodies to cross-reactive antigens, such as factor H binding protein (rLP2086) or a mix of outer membrane vesicle, factor H binding protein and other minor antigens (4CMenB). The true protective coverage among circulating MenB isolates afforded by these vaccines is unknown. Carefully conducted Phase IV post-implementation evaluations designed to measure specific effectiveness against major circulating MenB clonal lineages are needed to address the critical question of which antigens are linked to protection. Progress with whole-genome sequencing and bio-informatics may allow the composition of antigen mozaics based on two major outer membrane proteins: PorA and FetA.</p> </abstract>